Cognitive and neuropsychiatric disorders among MS patients from Latin America

Vanotti, Sandra; Cáceres, Fernando

doi:10.1177/2055217317717508

Cited by 15 publications

(6 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other epidemiological studies reported frequencies of cognitive impairment in patients with MS between 40–70% in North America and Europe [19]. Frequencies of 40–60% have been reported in Latin America [20]. Even though a variety of different methodological approaches and neuropsychological batteries have been used, results are very similar across all reported populations.…”

Section: Cognitive Impairment In Multiple Sclerosismentioning

confidence: 75%

Assessment and Impact of Cognitive Impairment in Multiple Sclerosis: An Overview

2019

View full text Add to dashboard Cite

Cognitive impairment affects 40–60% of patients with multiple sclerosis. It may be present early in the course of the disease and has an impact on a patient’s employability, social interactions, and quality of life. In the last three decades, an increasing interest in diagnosis and management of cognitive impairment has arisen. Neuropsychological assessment and neuroimaging studies focusing on cognitive impairment are now being incorporated as primary outcomes in clinical trials. However, there are still key uncertainties concerning the underlying mechanisms of damage, neural basis, sensitivity and validity of neuropsychological tests, and efficacy of pharmacological and non-pharmacological interventions. The present article aimed to present an overview of the assessment, neural correlates, and impact of cognitive impairment in multiple sclerosis.

show abstract

Section: Cognitive Impairment In Multiple Sclerosismentioning

confidence: 75%

Assessment and Impact of Cognitive Impairment in Multiple Sclerosis: An Overview

2019

View full text Add to dashboard Cite

show abstract

“…Moreover, another disabling consequence of MS is cognitive impairment (CI). This can affect 40-70% of patients at any time throughout disease progression ( 10 , 11 ). Attention, working memory and executive function are commonly affected in patients with MS ( 12 , 13 ).…”

Section: Introductionmentioning

confidence: 99%

Low‑field magnetic stimulation improved cuprizone‑induced depression‑like symptoms and demyelination in female mice

et al. 2022

View full text Add to dashboard Cite

Depression is a common and disabling comorbidity of multiple sclerosis (MS), with currently no clear guidelines for treatment. Low-field magnetic stimulation (LFMS), a novel non-invasive neuromodulation intervention, has been previously demonstrated to rapidly alleviate mood disorders. The aim of the present study was to investigate the effects of LFMS on depression-like behaviors and demyelination in a well-established mouse model of MS. C57BL/6 female mice were fed a 0.2% cuprizone (CPZ) diet for 3 or 6 weeks to induce acute demyelination. During this time, the mice were treated with either sham or LFMS for 20 min/day, 5 days/week. After 3 or 6 weeks of treatment, behavior was assessed with the open field task, Y-maze and the forced swim test. The prefrontal cortex and hippocampus were then collected to perform immunohistochemistry and western blot analysis to verify myelination status. The CPZ diet did not cause significant locomotor deficits; however, working memory, measured using the Y maze, depression-like behavior and adaptive learning, assayed using the forced swim test, were significantly impaired in these animals. LFMS treatment demonstrated a significant antidepressant-like effect and markedly attenuated the CPZ-induced demyelination in the prefrontal cortex after 3-and 6-weeks of treatment, as observed by changes in myelin basic protein immunostaining and western blot analysis. Therefore, the results of the present study indicated that LFMS may be a promising therapy for demyelinating diseases due to the improvement of depressive symptoms via regulation of myelination in cortical areas.

show abstract

“…Other psychiatric manifestations have a lower prevalence in MS. Emotional incontinence, characterised by uncontrollable episodes of laughing and crying, has been reported in about 10% of PwMS 10. It is due to a dissociation from the underlying emotional experience, thus resulting in incongruent emotional expression.…”

Section: Prevalence Clinical Characteristics and Impact Of Psychiatri...mentioning

confidence: 99%

Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction

Menculini

Mancini

Gaetani

et al. 2023

J Neurol Neurosurg Psychiatry

View full text Add to dashboard Cite

Psychiatric symptoms frequently occur in multiple sclerosis (MS), presenting with a complex phenomenology that encompasses a large clinical spectrum from clear-cut psychiatric disorders up to isolated psychopathological manifestations. Despite their relevant impact on the overall disease burden, such clinical features are often misdiagnosed, receive suboptimal treatment and are not systematically evaluated in the quantification of disease activity. The development of psychiatric symptoms in MS underpins a complex pathogenesis involving both emotional reactions to a disabling disease and structural multifocal central nervous system damage. Here, we review MS psychopathological manifestations under a biological perspective, highlighting the pathogenic relevance of synaptic and neural network dysfunction. Evidence obtained from human and experimental disease models suggests that MS-related psychiatric phenomenology is part of a disconnection syndrome due to diffuse inflammatory and neurodegenerative brain damage.

show abstract

Cognitive and neuropsychiatric disorders among MS patients from Latin America

Cited by 15 publications

References 78 publications

Assessment and Impact of Cognitive Impairment in Multiple Sclerosis: An Overview

Assessment and Impact of Cognitive Impairment in Multiple Sclerosis: An Overview

Low‑field magnetic stimulation improved cuprizone‑induced depression‑like symptoms and demyelination in female mice

Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction

Contact Info

Product

Resources

About